Showing 1991-2000 of 2157 results for "".
- ASAPS 2016: Labiaplasty More Than A Fadhttps://modernaesthetics.com/news/asaps-2016-labiaplasty-more-than-a-fad/2472263/When it rains, it pours. Both the American Society of Plastic Surgeons (ASPS) and sister organization American Society for Aesthetic Plastic Surgery (ASAPS) released some (ASAPS) or all (ASPS) of their annual statistics. And by and
- ASPS 2016 Stats: Cosmetic Surgery On The Risehttps://modernaesthetics.com/news/asps-2016-stats-cosmetic-surgery-on-the-rise/2472267/Fat is still phat – at least in some places like the breasts, butt and face, according to the annual statistics from the American Society of Plastic Surgeons (ASPS). Specifically, minimally invasive cosmetic fat injections incre
- In a Week of Surprising Acquisitions, Will Syneron Be Next?https://modernaesthetics.com/news/in-a-week-of-surprising-acquisitions-will-syneron-be-next/2472276/Hot off the heels of Allergan’s acquisition of Zeltiq and Hologic Inc,’s surprising purchase of Cynosure Inc., media reports are now swirling that British private equity fund Apax Partners is looking to buy Syneron Medical for $350-$400 million. According to Israeli finan
- Cynosure to Be Acquired by Hologichttps://modernaesthetics.com/news/cynosure-to-be-acquired-by-hologic/2472278/Hologic, Inc. and Cynosure, Inc. have signed a definitive agreement for Hologic to acquire all outstanding Cynosure shares for $66.00 per share in cash, which corresponds to an equity value of approximately $1.65 billion
- Update: Revance Starts Phase III Studies on RT002 for Frown Lineshttps://modernaesthetics.com/news/revance-starts-phase-iii-studies-on-rt002-for-frown-lines/2472297/Revance Therapeutics began two double-blind, placebo-controlled, North American Phase III trials to evaluate single injections of DaxibotulinumtoxinA (RT002) for the treatment glabellar lines in about 600 total patients. These pivotal trials
- Merz On The Move: Reflections On Fiscal Year 2015/16https://modernaesthetics.com/news/merz-on-the-move-reflections-on-fiscal-year-201516/2472311/Merz Pharma’s core business has grown by 8.9 percent from EUR 809.8 million to EUR 881.9 million in fiscal 2015/16, the company reports. The company’s total revenue of EUR 1,092.9 million has declined by 5.5 percent compared to previous year
- AAD Selects ContextMedia:Health as Patient Education Affinity Partnerhttps://modernaesthetics.com/news/aad-selects-contextmediahealth-as-patient-education-affinity-partner/2472318/ContextMedia:Health is now an Affinity Partner with the American Academy of Dermatology (AAD). The partnership offers ContextMedia:Health's suite of digital technology to the AAD's U.S. members at no cost. The agreement also bring
- Lisa Cassileth, MD, FACShttps://modernaesthetics.com/profiles/lisa-cassileth-md-facs/7ZBx2Q/
- Lisa Ishii, MDhttps://modernaesthetics.com/profiles/lisa-ishii-md/jlDlyr/
- Lisa Espinoza, MDhttps://modernaesthetics.com/profiles/lisa-espinoza-md/7vRQXr/